Indication

Treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Medicine details

Medicine name:
tafamidis (Vyndaqel)
SMC ID:
SMC2426
Pharmaceutical company
Pfizer Ltd
BNF chapter
Cardiovascular system
Submission type
Resubmission
Publication due date:
13 December 2021
SMC meeting date:
02 November 2021